PDGFRA and neoplasm: By analyzing factors such as tumor mutational status, expression of therapeutic targets (e.g., KIT and PDGFRA), and treatment response patterns, AI can predict the efficacy of targeted therapies such as tyrosine kinase inhibitors (TKIs), facilitating personalized treatment strategies and minimizing unnecessary interventions [69,70].